Denali Therapeutics Inc (DNLI) Stock Price, Quote & News

Company Profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Synd...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 866 8547

Website: www.denalitherapeutics.com

Address:

161 Oyster Point Boulevard, South San Francisco, United States

ZacksResearch Jul. 8 at 5:37 PM

$DNLI just got Priority Review — here's why that matters 👀 The FDA accepted Denali's BLA for its Hunter syndrome drug, putting it on the fast track toward potential approval and commercial launch. See what this means for the stock's next phase 👉 https://www.zacks.com/stock/news/2567417/dnlis-bla-for-hunter-syndrome-drug-gets-fdas-priority-review?cid=sm-stocktwits-2-2567417-teaser-994&ADID=SYND_STOCKTWITS_TWEET_2_2567417_TEASER_994

0 · Reply

ZacksResearch Jul. 8 at 1:36 PM

$DNLI drops 30.1% YTD — is it a comeback story in the making? 🔄 The FDA has accepted Denali's BLA for tividenofusp alfa with Priority Review, setting a target action date of Jan. 5, 2026. This could potentially turn DNLI into a commercial-stage biotech. Find out if DNLI’s road to approval could reverse its fortunes 👉 https://www.zacks.com/stock/news/2567417/dnlis-bla-for-hunter-syndrome-drug-gets-fdas-priority-review?cid=sm-stocktwits-2-2567417-body-911&ADID=SYND_STOCKTWITS_TWEET_2_2567417_BODY_911

0 · Reply

BigSqueezeComing Jul. 7 at 12:19 PM

$DNLI Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II) By Denali Therapeutics Inc. | July 07, 2025, 8:00 AM

0 · Reply

DoctrBenway Jul. 7 at 12:12 PM

$DNLI https://investors.denalitherapeutics.com/static-files/023214d5-b1b1-40e6-bd7c-661b00a0658d

0 · Reply

brbrown Jul. 3 at 12:23 PM

$DNLI

0 · Reply

ChristopherBrecher Jul. 3 at 11:42 AM

$DNLI Biotechs are always risky, but here is another ok looking chart.

0 · Reply

Biobullshitsniffer Jul. 3 at 6:13 AM

$DNLI Grok says this has good chance of getting an adcom as its novel treatment.

1 · Reply

Biobullshitsniffer Jul. 3 at 5:54 AM

$DNLI So they completed submission of BLA in May for Hunter syndrome. When do we expect the pdufa date?

1 · Reply

NextBigRun Jun. 20 at 2:43 AM

GLMD is the definition of asymmetric. No debt. Under cash. Biotech catalysts incoming. Float already pushed it to $2.08 on air imagine what happens with real news behind it. $ARWR $NBSE $SANA $DNLI …

0 · Reply

Winning_calls Jun. 11 at 4:59 PM

$DNLI 😉🤞🤞

0 · Reply

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

May 6, 2025, 4:01 PM EDT - 2 months ago

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

Apr 2, 2025, 8:00 AM EDT - 3 months ago

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Mar 27, 2025, 7:40 AM EDT - 3 months ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN GPCR INSM MRK SWTX

Mar 20, 2025, 2:16 PM EDT - 4 months ago

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead

Feb 27, 2025, 4:01 PM EST - 4 months ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Feb 6, 2025, 11:42 AM EST - 5 months ago

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Jan 15, 2025, 2:26 PM EST - 6 months ago

Why Is Denali Therapeutics Stock Trading Higher On Wednesday?

Jan 9, 2025, 3:56 PM EST - 6 months ago

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains

Jan 6, 2025, 4:43 PM EST - 6 months ago

Denali Therapeutics ALS drug fails in mid-stage trial

Jan 6, 2025, 4:30 PM EST - 6 months ago

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Jan 3, 2025, 1:08 PM EST - 6 months ago

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Nov 16, 2024, 8:56 AM EST - 8 months ago

Denali Has A Neurodegenerative Edge Despite Market Skepticism

Nov 6, 2024, 4:01 PM EST - 9 months ago

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Sep 3, 2024, 8:00 AM EDT - 11 months ago

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

Aug 19, 2024, 10:55 PM EDT - 11 months ago

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Aug 14, 2024, 2:00 PM EDT - 1 year ago

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

Aug 1, 2024, 6:45 AM EDT - 1 year ago

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

May 13, 2024, 12:30 PM EDT - 1 year ago

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

May 7, 2024, 4:01 PM EDT - 1 year ago

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 1, 2024, 8:00 AM EDT - 1 year ago

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Mar 6, 2024, 10:05 PM EST - 1 year ago

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Feb 27, 2024, 8:05 AM EST - 1 year ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Feb 27, 2024, 8:00 AM EST - 1 year ago

Denali Therapeutics Announces $500 million Private Placement Equity Financing

Feb 7, 2024, 8:00 AM EST - 1 year ago

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

Feb 1, 2024, 8:00 AM EST - 1 year ago

Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™

Jan 8, 2024, 8:00 AM EST - 1 year ago

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Nov 7, 2023, 4:01 PM EST - 1 year ago

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 2, 2023, 5:26 AM EDT - 1 year ago

Denali's New Summit: Changing Hunter Syndrome Landscape

Sep 11, 2023, 6:30 AM EDT - 2 years ago

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

FHTX MCRB MRNA SANA

Aug 30, 2023, 8:30 AM EDT - 2 years ago

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Jul 23, 2023, 12:51 AM EDT - 2 years ago

MPS II And Beyond: Implications Of Denali's Promising Pipeline

Jun 21, 2023, 6:00 AM EDT - 2 years ago

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

FHTX MCRB MRNA SANA

Jun 20, 2023, 7:00 AM EDT - 2 years ago

Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)

May 8, 2023, 4:01 PM EDT - 2 years ago

Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Apr 17, 2023, 6:52 AM EDT - 2 years ago

Denali Therapeutics: Pioneering The Neurodegenerative Space With Blood-Brain Barrier Innovations

Apr 12, 2023, 8:00 AM EDT - 2 years ago

Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta

Apr 10, 2023, 8:00 AM EDT - 2 years ago

Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting

Feb 27, 2023, 4:01 PM EST - 2 years ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Feb 22, 2023, 4:33 PM EST - 2 years ago

Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™

Feb 15, 2023, 4:01 PM EST - 2 years ago

Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™

Jan 25, 2023, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi

Jan 16, 2023, 12:15 PM EST - 2 years ago

Denali: Need Patient Data To Justify That High Valuation

Jan 9, 2023, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Dec 21, 2022, 10:55 AM EST - 2 years ago

7 Best Small-Cap Stocks to Buy for 2022 and Beyond

ARVN AXSM FATE GTLS RCKT

Dec 5, 2022, 7:00 AM EST - 2 years ago

Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial

Nov 3, 2022, 4:01 PM EDT - 2 years ago

Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Nov 1, 2022, 8:00 AM EDT - 2 years ago

Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN

ZacksResearch Jul. 8 at 5:37 PM

0 · Reply

ZacksResearch Jul. 8 at 1:36 PM

0 · Reply

BigSqueezeComing Jul. 7 at 12:19 PM

0 · Reply

DoctrBenway Jul. 7 at 12:12 PM

$DNLI https://investors.denalitherapeutics.com/static-files/023214d5-b1b1-40e6-bd7c-661b00a0658d

0 · Reply

brbrown Jul. 3 at 12:23 PM

$DNLI

0 · Reply

ChristopherBrecher Jul. 3 at 11:42 AM

$DNLI Biotechs are always risky, but here is another ok looking chart.

0 · Reply

Biobullshitsniffer Jul. 3 at 6:13 AM

$DNLI Grok says this has good chance of getting an adcom as its novel treatment.

1 · Reply

Biobullshitsniffer Jul. 3 at 5:54 AM

$DNLI So they completed submission of BLA in May for Hunter syndrome. When do we expect the pdufa date?

1 · Reply

NextBigRun Jun. 20 at 2:43 AM

0 · Reply

Winning_calls Jun. 11 at 4:59 PM

$DNLI 😉🤞🤞

0 · Reply

swingingtech Jun. 9 at 1:25 PM

$VB $DNLI $AZTA $VMEO https://wallstreetwaves.com/analysts-project-vb-to-reach-270/

0 · Reply

Winning_calls Jun. 9 at 3:41 AM

$DNLI pick me up @ $15.15

0 · Reply

BobBijawklah Jun. 6 at 3:17 PM

$ACAD couple good stocks for everyone to research and see if it makes a good investmetn for me these work. $DNLI Denali theraputics . First listen to ryan watts and look at his education and mannerisms a true leader. they have a submission to fda for hunters disease no cure 100% mortality rate. $RCKT two drugs out for approval to fda one has a manufacturing crl but again they are all ultra orphan rare diseease with no standard of care of an ineffective standard of care. The stock dropped due to a patient death in another late stage trial. Death happened because they added a conditioning agent to several patients who were enrolled . A rare side effect of that conditioning agent is capilary leak syndrome. So i am confident the fda releases the hold when they update and remove that conditioning agent from the pre treatment protocol. I am more confident and comfortable with denali than rocket because of RFK jr and his reluctance to endorse expensive genetic modifying drugs.

0 · Reply

TimRegan_WTR May. 29 at 5:50 PM

$ABBV $ALEC $DNLI $NVS $TAK

0 · Reply

research_WTR May. 29 at 5:42 PM

TREM2 Agonists: A New Frontier in Neurodegeneration Despite past clinical setbacks, Sanofi’s $470–$600M acquisition of Vigil Neuroscience signals renewed confidence in TREM2 as a key neuroinflammation target in Alzheimer’s and other disorders. 🔹 TREM2 helps microglia clear toxic proteins and regulate inflammation in the CNS 🔹 Past mAb candidates (ALEC/ABBV, DNLI) failed in trials due to lack of efficacy or safety concerns 🔹 Vigil’s oral TREM2 agonist (VG-3927) showed strong Phase 1 data and heads to Phase 2 in 2H25 🔹 Sanofi’s support may reshape the future of microglia-targeted neurotherapies Subscribe at our website to follow along with Robert Sassoon! $ALEC $ABBV $DNLI $TAK $NVS

0 · Reply

Carl_K May. 22 at 4:53 AM

$SNY $VIGL $INMB $ALEC $DNLI Sanofi - Vigil buyout, ~400% premium, TREM2 / microglia modulation for AD, VG-3927 is Phase 2-ready, $470 million deal. Microglia and brain immune cell modulation are the important targets here. Cfr. my blog on them from 2022. If not mistaken, TREM2 is a target that's failed to show substantial impact so far. Alector and Denali (listed as competitors in INmune's 10K) were leaders in that regard. Difficulty: you're manipulating cells with very complex behaviors (microglia) simply because TREM2 appears implicated in CNS diseases. https://www.thetyp.com/post/the-10-billion-unicorn-in-inmune-bio-it-s-the-micro-glia-stupid

3 · Reply

JarvisFlow May. 19 at 5:57 PM

B of A Securities has adjusted their stance on Denali Therapeutics ( $DNLI ), setting the rating to Buy with a target price of 28 → 27.

0 · Reply

BioTechHealthX May. 11 at 3:53 AM

$DNLI With new manufacturing facilities, & major partnerships, Denali Therapeutics is positioned for rapid growth. https://biotechhealthx.com/biotech-news/denali-therapeutics-the-future-of-neuroscience-innovation/

0 · Reply

JarvisFlow May. 8 at 1:00 PM

Baird has updated their rating for Denali Therapeutics ( $DNLI ) to Outperform with a price target of 29.

0 · Reply

ZacksResearch May. 7 at 5:21 PM

$DNLI just reported a wider-than-expected loss — is the pipeline enough to turn things around? 🔍 💸 Q1 loss of 78 cents per share vs. Zacks Consensus Estimate of 71 cents 🚫 No collaboration revenues this quarter. 🚀 BLA for tividenofusp alfa submitted under FDA’s accelerated approval pathway Cash reserves of $1.05 billion give room to maneuver! Is this the moment to buy into potential? Discover the full analysis here 👉 https://www.zacks.com/commentary/2464381/denali-q1-loss-wider-than-expected-hunter-syndrome-drug-in-focus?cid=sm-stocktwits-2-2464381-body&ADID=SYND_STOCKTWITS_TWEET_2_2464381_BODY

0 · Reply

JarvisFlow May. 7 at 1:38 PM

HC Wainwright & Co. has adjusted their stance on Denali Therapeutics ( $DNLI ), setting the rating to Buy with a target price of 80 → 32.

0 · Reply

Estimize May. 6 at 8:25 PM

$DNLI reported -0.78 EPS and 0.00 revenue for Q1. http://www.estimize.com/intro/dnli?chart=historical&metric_name=eps&utm_content=DNLI&utm_

0 · Reply

Market Cap	2.13B
Revenue (ttm)	0.00
Net Income (ttm)	-422.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,447,300
Avg Vol	1,489,396
Day's Range	N/A - N/A
Shares Out	145.28M
Stochastic %K	16%
Beta	1.33
Analysts	Strong Sell
Price Target	$32.53